RE-BVS – Piemonte Repository

Sfoglia per AUTORE
ANTONUZZO L
Collezione AO Cuneo

Items : 5

Body composition parameters predict pathological response and outcomes in locally advanced gastric cancer after neoadjuvant treatment: A multicenter, international study. in Clinical nutrition (Edinburgh, Scotland) / Clin Nutr. 2021 Aug;40(8):4980-4987. doi: 10.1016/j.clnu.2021.06.021. Epub 2021 Jun 25.

2021
AO Cuneo

Lin JX; Tang YH; Zhou WX; Desiderio J; Parisi A; Xie JW; Wang JB; Cianchi F; Antonuzzo L; Borghi F; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Staderini F; Marano A; Peluso C; Li P; Zheng CH; Ma YB; Huang CM; Lin JX; Tang YH; Zhou WX; Desiderio J; Parisi A; Xie JW; Wang JB; et alii...

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. in The Lancet. Oncology / Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.

2020
AO Cuneo
AOU Città della Salute di Torino

Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Falcone A; Boni L; Zagonel V; Ugolini C; Fontanini G; Corgna E; Cupini S; Mammoliti S; Fenocchio E; Roselli M; Mambrini A; Ritorto G; Di Donato S; Clavarezza M; Carlomagno C; Ronzoni M; Tomasello G; Masi G; Antonuzzo L; Cordio S; Moretto R; Corallo S; Granetto C; Buonadonna A; Zaniboni A; et alii...

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. in Gastroenterology / Gastroenterology. 2018 Aug;155(2):479-489.e7. doi: 10.1053/j.gastro.2018.04.010. Epub 2018 Apr 13.

2018
AO Cuneo
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Mazzaferro V; Buzzoni R; Delle Fave G; Giacomelli L; Milione M; Lo Russo G; Concas L; Femia D; Prinzi N; Garattini SK; Bajetta E; Tafuto S; Di Costanzo F; Torniai M; Zaniboni A; Ortolani S; Puliafito I; Panzuto F; Colao A; Brighi N; La Salvia A; Cavalcoli F; Bongiovanni A; Fazio N; Ricci S; Duro M; Davì MV; Cauchi C; Carnaghi C; et alii...

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. in ESMO open / ESMO Open. 2018 Jul 9;3(4):e000403. doi: 10.1136/esmoopen-2018-000403. eCollection 2018.

2018
AO Cuneo

Borelli B; Moretto R; Lonardi S; Bonetti A; Antoniotti C; Pietrantonio F; Masi G; Burgio V; Marmorino F; Salvatore L; Rossini D; Zaniboni A; Zucchelli G; Martignetti A; Di Battista M; Pella N; Passardi A; Boccaccino A; Leone F; Colombo C; Granetto C; Vannini F; Marsico VA; Martinelli E; Antonuzzo L; Vitello S; Delliponti L; Boni L; Cremolini C; et alii...

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2015 Apr;26(4):724-730. doi: 10.1093/annonc/mdv012. Epub 2015 Jan 18.

2015
AO Cuneo

Masi G; Salvatore L; Boni L; Loupakis F; Cremolini C; Fornaro L; Schirripa M; Cupini S; Barbara C; Safina V; Granetto C; Fea E; Antonuzzo L; Boni C; Allegrini G; Chiara S; Amoroso D; Bonetti A; Falcone A;